Atherosclerosis Treatment DrugsMarket - Driver
Increasing number of pipelinestudies and rising involvement of key players for developing the treatmentoptions for atherosclerosis are expected to propel AtherosclerosisTreatment Drugs Market growth. For Instance, in November 13, 2018, Bayer incollaboration with Janssen, LP started the clinical study for Rivaroxaban andAcetylsalicylic Acid to build up the insights in treatment patterns and tostudy results of Rivaroxaban (Xarelto) in combination with acetylsalicylic acid(xatoa) prescribed to patients with atherosclerosis. The study is estimated tocomplete in August 2021.
Moreover, technologicaladvancement in the atherosclerosis treatment procedures is expected to boostthe atherosclerosis treatments drug market growth. For instance, in May 2017,Researchers at Ben-Gurion University (BGU) and the Sheba Medical Centerdeveloped Nano polymer therapy, a new therapy for the treatment ofatherosclerosis. It prevents heart failure with a new biomedical polymer(E-selectin-targeting polymer) that reduces arterial plaque and inflammation inthe cardiovascular system. E-selectin-targeting polymer helps to reduceexisting plaque and impedes the further plaque formation. It also preventsarterial thrombosis, ischemia, myocardial infarction, and strokes.
Atherosclerosis is characterizedby the narrowing and hardening of the arteries. In this condition, arteriesbecome blocked by fatty substances, such as cholesterol. These substances arecalled as plaques or atheroma. The risks of atherosclerosis increase with age.The deposition of plaque tends to narrow the arterial canal, which result inthe limited flow of blood and oxygen through it. Atherosclerosis commences withdamage to the endothelium of arteries leading to the formation of plaque. Thiscondition is dangerous for the vital organs such as heart and brain.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2430
The risk associated withatherosclerosis includes serious cardiovascular and brain diseases.Collectively, these conditions are more common for cardiovascular diseases(CVD) including coronary heart disease, angina pectoris, and transitoryischemia. Other risks for atherosclerosis are carotid artery disease, kidneydisease, and peripheral artery disease.
Atherosclerosis Treatment DrugsMarket- Restraints
However, the side effectsassociated with atherosclerosis drugs and limited efficacy of the drugs isexpected to hamper atherosclerosis market growth. For instance, in November2016, The Lancet led by Rory Collins, provided an evidence on statin therapyand the methodological limitations. As per data, statins are associated withincreased incidence of diabetes and hemorrhagic stroke. Statins tends to increasethe risk of type 2 diabetes in a dose-dependent mode.
Atherosclerosis Treatment DrugsMarket- Regional Analysis
On the basis of region, theglobal atherosclerosis treatment drugs market is segmented into North America,Latin America, Europe, Asia Pacific, Middle East, and Africa.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/atherosclerosis-treatment-drugs-market-2430
Geographically, North America isexpected to gain significant market share over the forecast period, owing toincreasing incidences of atherosclerotic condition among the population in thisregion. For instance, in November 2016, as per data provided by the U.S.Centers for Disease Control and Prevention (CDC) and the World HealthOrganization (WHO), there were more than 15.5 million Americans who hadcoronary artery disease and it is expected that for every 42 seconds an Americanwill experience the onset of a myocardial infarction.
Furthermore, Asia Pacific isexpected to witness significant growth in the market, owing to expansion ofmajor key players in this region. For instance, in October 2017, GSK opened itsnew regional headquarters for Asia in Singapore. The GSK’s purpose for buildingheadquarters is to support the pharmaceutical, vaccines, and consumerhealthcare businesses across multiple regions in Asia Pacific.
Key players operating in theAtherosclerosis treatment drugs market include GlaxoSmithKline plc. Merck &Co., Inc., F. Hoffmann-La Roche Ltd., Isis Pharmaceuticals, Inc., AntheraPharmaceuticals, Novartis AG, Sanofi, Johnson and Johnson, Bayer AG, TheMedicine Company, and Cardium Therapeutics.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2430
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
